BioGaia, a Swedish biotechnology company, has extended its agreement withFerring Pharmaceuticals over BioGaia's probiotics drops. The Swiss-based biopharmaceutical company has the rights to sell BioGaia's probiotic drops in Ireland and exclusive selling rights to the probiotic drops and tablets in Bahrain, Yemen, Qatar, Oman, Kuwait and the United Arab Emirates. BioGaia's products are based primarily on the lactic acid bacterium Lactobacillus reuteri, which the company claims has probiotic, health-enhancing effects. The two companies signed an initial agreement in March 2006, allowing Ferring to sell the drops in Spain, Portugal, Czech Republic and Hungary. The agreement was extended to Mexico, Brazil and Greece in August.
BioGaia and Ferring extend probiotic sales agreement
Listen to this article
BioGaia, a Swedish biotechnology company, has extended its agreement withFerring Pharmaceuticals over BioGaia's probiotics drops. The Swiss-based biopharmaceutical company has the rights to sell BioGaia's probiotic drops in Ireland and exclusive selling rights to the probiotic drops and tablets in Bahrain, Yemen, Qatar, Oman, Kuwait and the United Arab Emirates. BioGaia's products are based primarily on the lactic acid bacterium Lactobacillus reuteri, which the company claims has probiotic, health-enhancing effects. The two companies signed an initial agreement in March 2006, allowing Ferring to sell the drops in Spain, Portugal, Czech Republic and Hungary. The agreement was extended to Mexico, Brazil and Greece in August.
Keep up with the top pharma business news of the week. On the go.
More from Business
- • By
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
- • By
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
More from Scrip
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
